pertuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4957	380610-27-5

Description:

Molecule	Description
Synonyms: pertuzumab perjeta rhuMAb 2C4 pertuzumab (genetical recombination)	a humanized HER-2 monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

pertuzumab
perjeta
rhuMAb 2C4
pertuzumab (genetical recombination)

a humanized HER-2 monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
March 4, 2013	EMA
June 8, 2012	FDA	GENENTECH
June 28, 2013	PMDA	Chugai Pharmaceutical

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	1584.12	18.45	618	47992	23085	63417327
Diarrhoea	1345.21	18.45	2136	46474	713230	62727182
Ejection fraction decreased	1043.93	18.45	451	48159	21881	63418531
Neuropathy peripheral	626.91	18.45	589	48021	113078	63327334
Disease progression	601.45	18.45	596	48014	122162	63318250
Metastases to central nervous system	548.45	18.45	245	48365	12860	63427552
Polyneuropathy	510.96	18.45	241	48369	14348	63426064
Febrile neutropenia	442.58	18.45	498	48112	117951	63322461
Mucosal inflammation	371.19	18.45	299	48311	46629	63393783
Neutropenia	361.04	18.45	549	48061	174456	63265956
Cardiotoxicity	344.23	18.45	155	48455	8283	63432129
Palmar-plantar erythrodysaesthesia syndrome	233.20	18.45	170	48440	22845	63417567
Drug ineffective	233.08	18.45	276	48334	1044489	62395923
Chills	218.55	18.45	345	48265	113033	63327379
Interstitial lung disease	216.88	18.45	252	48358	61656	63378756
Peripheral sensory neuropathy	200.82	18.45	103	48507	7348	63433064
Neutropenic sepsis	193.32	18.45	133	48477	16305	63424107
Left ventricular dysfunction	179.98	18.45	113	48497	11875	63428537
Vascular device infection	179.66	18.45	95	48515	7217	63433195
Rheumatoid arthritis	175.18	18.45	4	48606	253815	63186597
Arthropathy	164.81	18.45	3	48607	234789	63205623
Joint swelling	164.21	18.45	27	48583	327639	63112773
Epistaxis	152.23	18.45	230	48380	72495	63367917
Metastases to lung	151.91	18.45	104	48506	12646	63427766
Abdominal discomfort	148.93	18.45	32	48578	320853	63119559
Pneumonitis	148.48	18.45	158	48452	35064	63405348
Product dose omission issue	146.82	18.45	8	48602	234305	63206107
Cardiac dysfunction	146.11	18.45	58	48552	2257	63438155
Drug hypersensitivity	142.12	18.45	32	48578	310655	63129757
Metastases to bone	135.29	18.45	119	48491	20900	63419512
Hypokalaemia	132.76	18.45	264	48346	103540	63336872
Anaemia	129.51	18.45	505	48105	292925	63147487
Systemic lupus erythematosus	125.29	18.45	9	48601	208909	63231503
Off label use	124.74	18.45	912	47698	673550	62766862
Skin toxicity	123.67	18.45	64	48546	4650	63435762
Metastases to liver	123.31	18.45	119	48491	23520	63416892
Therapeutic product effect decreased	119.76	18.45	7	48603	193180	63247232
Metastasis	117.80	18.45	64	48546	5133	63435279
Fall	117.73	18.45	78	48532	392256	63048156
Breast cancer recurrent	111.20	18.45	58	48552	4283	63436129
Pain	107.67	18.45	257	48353	740371	62700041
Pleural effusion	102.68	18.45	223	48387	92987	63347425
Nail dystrophy	101.92	18.45	36	48574	1007	63439405
Erysipelas	100.17	18.45	67	48543	7838	63432574
Musculoskeletal stiffness	99.93	18.45	12	48598	184606	63255806
Exposure during pregnancy	98.38	18.45	5	48605	155542	63284870
Condition aggravated	97.06	18.45	99	48511	402118	63038294
Onycholysis	96.36	18.45	39	48571	1597	63438815
Stomatitis	95.04	18.45	277	48333	138448	63301964
Dysgeusia	93.86	18.45	145	48465	46565	63393847
Lymphoedema	93.42	18.45	75	48535	11617	63428795
Nail toxicity	93.30	18.45	26	48584	323	63440089
Drug intolerance	93.03	18.45	61	48549	308600	63131812
Metastases to lymph nodes	91.20	18.45	64	48546	8094	63432318
Sinusitis	91.09	18.45	30	48580	226623	63213789
Cardiac failure	90.01	18.45	206	48404	88936	63351476
Device related infection	89.96	18.45	100	48510	23292	63417120
Vomiting	88.38	18.45	730	47880	558887	62881525
Cardiomyopathy	87.00	18.45	86	48524	17498	63422914
Decreased appetite	86.54	18.45	401	48209	250651	63189761
Bone pain	86.06	18.45	152	48458	54489	63385923
Discomfort	85.54	18.45	13	48597	167361	63273051
Neoplasm progression	84.55	18.45	121	48489	36307	63404105
Hepatic enzyme increased	84.49	18.45	25	48585	202303	63238109
Lacrimation increased	82.46	18.45	90	48520	20541	63419871
Treatment failure	82.37	18.45	25	48585	199018	63241394
Neutrophil count decreased	81.32	18.45	151	48459	56255	63384157
Drug interaction	77.98	18.45	39	48571	229092	63211320
Nail disorder	74.52	18.45	69	48541	12946	63427466
Nail discolouration	74.05	18.45	38	48572	2712	63437700
Injection site pain	73.90	18.45	7	48603	129793	63310619
Confusional state	73.55	18.45	45	48565	236335	63204077
Neurotoxicity	72.97	18.45	77	48533	16913	63423499
Mastitis	72.71	18.45	37	48573	2595	63437817
Pericarditis	72.57	18.45	8	48602	131571	63308841
Dermatitis acneiform	72.25	18.45	46	48564	4950	63435462
Swelling	69.57	18.45	65	48545	275313	63165099
Mastectomy	66.59	18.45	30	48580	1603	63438809
Metastases to skin	66.07	18.45	30	48580	1633	63438779
Paronychia	65.35	18.45	45	48565	5520	63434892
Pyrexia	64.90	18.45	596	48014	469882	62970530
Glossodynia	64.63	18.45	28	48582	178848	63261564
Nausea	64.52	18.45	963	47647	853508	62586904
Hyperpyrexia	64.16	18.45	38	48572	3594	63436818
Breast cancer metastatic	63.61	18.45	61	48549	11957	63428455
Cellulitis	62.30	18.45	170	48440	81788	63358624
Recall phenomenon	61.86	18.45	22	48588	628	63439784
Product use in unapproved indication	61.64	18.45	30	48580	179050	63261362
Arthritis	61.57	18.45	8	48602	115913	63324499
Wound	61.50	18.45	24	48586	163239	63277173
Radiation skin injury	60.82	18.45	24	48586	919	63439493
Mobility decreased	60.56	18.45	10	48600	121149	63319263
Maternal exposure during pregnancy	60.37	18.45	48	48562	220014	63220398
Hyperfibrinogenaemia	59.68	18.45	12	48598	28	63440384
Breast pain	59.00	18.45	51	48559	8747	63431665
Excessive eye blinking	56.96	18.45	25	48585	1255	63439157
Onychoclasis	56.39	18.45	43	48567	6179	63434233
Tonsillar disorder	56.15	18.45	24	48586	1129	63439283
Cystitis noninfective	55.96	18.45	23	48587	980	63439432
Constipation	55.78	18.45	328	48282	224615	63215797
Product use issue	55.74	18.45	52	48558	220468	63219944
Inappropriate schedule of product administration	55.64	18.45	7	48603	103958	63336454
Dehydration	55.37	18.45	271	48339	173083	63267329
Meibomian gland dysfunction	55.24	18.45	15	48595	168	63440244
Osteoarthritis	54.64	18.45	5	48605	95338	63345074
Weight increased	53.39	18.45	73	48537	260719	63179693
Platelet count decreased	52.81	18.45	202	48408	115920	63324492
Impaired healing	52.29	18.45	8	48602	102534	63337878
Colitis	52.15	18.45	115	48495	48413	63391999
Thrombocytopenia	51.67	18.45	241	48369	150916	63289496
Duodenal ulcer perforation	51.55	18.45	4	48606	87205	63353207
Somnolence	51.53	18.45	37	48573	178648	63261764
Tumour pain	51.09	18.45	24	48586	1413	63438999
Chest discomfort	48.95	18.45	190	48420	109779	63330633
Nail infection	48.81	18.45	28	48582	2495	63437917
Breast neoplasm	48.10	18.45	23	48587	1409	63439003
Hypertransaminasaemia	47.77	18.45	40	48570	6569	63433843
Malignant neoplasm progression	46.91	18.45	154	48456	81967	63358445
Gait disturbance	46.51	18.45	43	48567	183135	63257277
Dry skin	46.25	18.45	121	48489	56766	63383646
Pseudocirrhosis	45.62	18.45	18	48592	689	63439723
Aortitis	44.42	18.45	20	48590	1067	63439345
Hot flush	43.84	18.45	111	48499	51048	63389364
Drug abuse	43.80	18.45	3	48607	72515	63367897
Arthralgia	43.57	18.45	257	48353	569453	62870959
Toxicity to various agents	43.17	18.45	77	48533	247173	63193239
Fatigue	43.14	18.45	934	47676	887094	62553318
Haematotoxicity	42.97	18.45	44	48566	9332	63431080
Asthma	42.93	18.45	22	48588	127539	63312873
Metastases to spine	42.28	18.45	28	48582	3221	63437191
Granulocyte count decreased	41.91	18.45	20	48590	1220	63439192
Onychomadesis	41.50	18.45	35	48575	5805	63434607
Folate deficiency	41.39	18.45	25	48585	2450	63437962
Dyspnoea	41.37	18.45	723	47887	660590	62779822
Madarosis	41.18	18.45	27	48583	3054	63437358
Biliary sepsis	40.84	18.45	18	48592	913	63439499
Blood cholesterol increased	40.37	18.45	11	48599	94021	63346391
Onychalgia	40.11	18.45	18	48592	953	63439459
Blood magnesium decreased	40.07	18.45	50	48560	13148	63427264
Systolic dysfunction	39.91	18.45	21	48589	1578	63438834
Bone marrow infiltration	39.24	18.45	16	48594	668	63439744
Enterocolitis infectious	39.20	18.45	21	48589	1637	63438775
Red cell distribution width increased	38.76	18.45	44	48566	10480	63429932
Hepatic function abnormal	38.76	18.45	87	48523	37055	63403357
Type 2 diabetes mellitus	37.55	18.45	3	48607	63865	63376547
Feeling abnormal	37.47	18.45	35	48575	148357	63292055
Osteonecrosis of jaw	37.47	18.45	83	48527	35040	63405372
Injury	36.70	18.45	6	48604	73241	63367171
Blood creatine increased	36.61	18.45	32	48578	5569	63434843
Suicidal ideation	36.51	18.45	3	48607	62418	63377994
Alopecia areata	36.11	18.45	20	48590	1665	63438747
Nasal disorder	35.63	18.45	24	48586	2840	63437572
Depression	35.37	18.45	60	48550	196432	63243980
Dyschezia	35.37	18.45	22	48588	2272	63438140
Contusion	34.90	18.45	38	48572	150006	63290406
Vessel puncture site bruise	34.54	18.45	13	48597	437	63439975
Bradycardia	34.53	18.45	7	48603	73220	63367192
Hyperchlorhydria	34.43	18.45	20	48590	1824	63438588
Pneumonitis chemical	34.38	18.45	11	48599	225	63440187
Odynophagia	34.07	18.45	35	48575	7451	63432961
Injection site reaction	33.72	18.45	3	48607	58521	63381891
Rectal haemorrhage	33.62	18.45	98	48512	48932	63391480
Therapeutic product effect incomplete	33.37	18.45	28	48582	125028	63315384
Therapy partial responder	33.36	18.45	41	48569	10617	63429795
Metastases to meninges	32.84	18.45	22	48588	2580	63437832
Adverse event	32.82	18.45	6	48604	67553	63372859
Breast inflammation	32.61	18.45	10	48600	177	63440235
Blister	32.32	18.45	31	48579	129783	63310629
Acute interstitial pneumonitis	32.14	18.45	14	48596	690	63439722
Flushing	32.00	18.45	128	48482	74959	63365453
Radiation pneumonitis	31.78	18.45	18	48592	1565	63438847
Hair colour changes	31.44	18.45	23	48587	3104	63437308
Gastrointestinal toxicity	31.33	18.45	34	48576	7707	63432705
Depressed level of consciousness	31.29	18.45	5	48605	62073	63378339
Irritable bowel syndrome	31.21	18.45	12	48598	82400	63358012
Breast disorder	30.99	18.45	21	48589	2509	63437903
Vascular fragility	30.67	18.45	9	48601	136	63440276
Leukopenia	29.98	18.45	128	48482	77162	63363250
Gait inability	29.75	18.45	3	48607	52956	63387456
Myalgia	29.66	18.45	203	48407	146326	63294086
Mucosal dryness	29.45	18.45	21	48589	2723	63437689
Ventricular hypokinesia	29.29	18.45	26	48584	4618	63435794
Overdose	29.21	18.45	27	48583	115051	63325361
Metastatic neoplasm	29.01	18.45	25	48585	4270	63436142
Tachycardia	28.41	18.45	171	48439	117985	63322427
Pituitary tumour	28.16	18.45	14	48596	934	63439478
Hypothalamo-pituitary disorder	28.08	18.45	13	48597	740	63439672
Delirium	28.04	18.45	3	48607	50538	63389874
Axillary pain	28.03	18.45	18	48592	1965	63438447
Anxiety	27.97	18.45	80	48530	217461	63222951
Post-traumatic pain	27.93	18.45	11	48599	419	63439993
Pericardial effusion	27.63	18.45	67	48543	29991	63410421
Nasal congestion	27.59	18.45	8	48602	65652	63374760
Metastases to bone marrow	27.16	18.45	11	48599	451	63439961
Secondary cerebellar degeneration	27.16	18.45	7	48603	63	63440349
Nail bed bleeding	27.13	18.45	10	48600	317	63440095
Hallucination	26.35	18.45	5	48605	54812	63385600
Osteitis condensans	26.16	18.45	6	48604	31	63440381
Wheezing	26	18.45	21	48589	95574	63344838
Hand dermatitis	25.88	18.45	9	48601	240	63440172
Alopecia	25.87	18.45	382	48228	337154	63103258
Enterocolitis	25.85	18.45	31	48579	7827	63432585
HER2 positive breast cancer	25.77	18.45	10	48600	366	63440046
Incorrect dose administered	25.76	18.45	7	48603	59961	63380451
Recurrent cancer	25.56	18.45	17	48593	1970	63438442
Autonomic neuropathy	25.51	18.45	14	48596	1145	63439267
Keratitis	25.33	18.45	21	48589	3401	63437011
Hair texture abnormal	25.27	18.45	23	48587	4220	63436192
Radiation necrosis	25.07	18.45	10	48600	394	63440018
Gastritis	25.03	18.45	74	48536	37229	63403183
Adverse drug reaction	25.00	18.45	15	48595	79699	63360713
Intracranial pressure increased	24.81	18.45	25	48585	5202	63435210
Illness	24.62	18.45	4	48606	49055	63391357
Bone marrow failure	24.52	18.45	63	48547	29227	63411185
Pulmonary embolism	24.41	18.45	163	48447	116521	63323891
Urticaria	24.36	18.45	57	48553	165745	63274667
Hypomagnesaemia	24.25	18.45	62	48548	28675	63411737
Metastases to soft tissue	24.25	18.45	8	48602	181	63440231
Agranulocytosis	24.15	18.45	57	48553	25077	63415335
Mitral valve incompetence	24.01	18.45	49	48561	19545	63420867
Hyperkalaemia	23.91	18.45	6	48604	54197	63386215
Dysuria	23.67	18.45	68	48542	33670	63406742
Vaginal prolapse	23.65	18.45	10	48600	458	63439954
Back pain	23.49	18.45	307	48303	263838	63176574
Neoplasm recurrence	23.40	18.45	18	48592	2620	63437792
Overflow diarrhoea	23.31	18.45	7	48603	115	63440297
Blood glucose increased	23.28	18.45	18	48592	83738	63356674
Catheter site bruise	23.19	18.45	10	48600	481	63439931
Catheter site pain	23.12	18.45	23	48587	4712	63435700
Paralysis recurrent laryngeal nerve	23.08	18.45	6	48604	56	63440356
White blood cell count abnormal	22.82	18.45	26	48584	6216	63434196
Central nervous system lesion	22.74	18.45	34	48576	10601	63429811
White blood cell count decreased	22.62	18.45	183	48427	138921	63301491
Vulvovaginal candidiasis	22.50	18.45	19	48591	3156	63437256
Palmar erythema	22.44	18.45	15	48595	1752	63438660
Cardio-respiratory arrest	22.26	18.45	9	48601	59950	63380462
Sarcoid-like reaction	22.11	18.45	5	48605	24	63440388
Migraine	22.07	18.45	28	48582	103318	63337094
Nephrolithiasis	22.04	18.45	3	48607	41981	63398431
Mucosal disorder	21.91	18.45	16	48594	2153	63438259
Paraesthesia	21.60	18.45	199	48411	156767	63283645
Hiccups	21.51	18.45	16	48594	2215	63438197
Skin infection	21.40	18.45	40	48570	14962	63425450
Peripheral swelling	21.32	18.45	118	48492	265824	63174588
Osteosclerosis	21.08	18.45	20	48590	3868	63436544
Mean platelet volume decreased	21.06	18.45	17	48593	2652	63437760
Lymphadenopathy	20.95	18.45	71	48539	38387	63402025
Medication error	20.84	18.45	7	48603	52277	63388135
Tongue coated	20.73	18.45	13	48597	1362	63439050
Retracted nipple	20.66	18.45	4	48606	7	63440405
Electrocardiogram QT prolonged	20.42	18.45	10	48600	59520	63380892
Osteolysis	19.96	18.45	17	48593	2857	63437555
Perforation	19.91	18.45	12	48598	1171	63439241
Mouth ulceration	19.86	18.45	63	48547	32921	63407491
Dandy-Walker syndrome	19.85	18.45	6	48604	101	63440311
Duodenal ulcer	19.83	18.45	27	48583	7729	63432683
Urinary tract infection	19.66	18.45	298	48312	264386	63176026
Hypermetabolism	19.61	18.45	7	48603	202	63440210
Rash follicular	19.60	18.45	5	48605	43	63440369
Axillary vein thrombosis	19.55	18.45	8	48602	337	63440075
Gastrointestinal haemorrhage	19.49	18.45	20	48590	81156	63359256
Ear infection	19.43	18.45	3	48607	38210	63402202
Vagus nerve disorder	19.22	18.45	6	48604	113	63440299
Dermatitis	19.14	18.45	41	48569	16917	63423495
Neck pain	19.13	18.45	15	48595	69303	63371109
Rhinorrhoea	19.13	18.45	100	48510	65477	63374935
Agitation	19.09	18.45	11	48599	59746	63380666
Hepatotoxicity	18.98	18.45	67	48543	36974	63403438
Anaphylactic shock	18.93	18.45	50	48560	23583	63416829
Cough	18.90	18.45	322	48288	292421	63147991
Therapeutic response decreased	18.71	18.45	12	48598	61513	63378899
Naevus haemorrhage	18.65	18.45	6	48604	125	63440287
Appendicitis	18.60	18.45	27	48583	8202	63432210

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Delusion of grandeur	144.91	62.75	28	1745	1132	34954026
Rhinalgia	110.65	62.75	22	1751	1031	34954127
Affective disorder	107.99	62.75	28	1745	4332	34950826
Schizophrenia	88.97	62.75	28	1745	8638	34946520
Lymphocyte count abnormal	84.59	62.75	18	1755	1180	34953978
Hallucination, auditory	80.22	62.75	28	1745	11889	34943269
Extrapyramidal disorder	78.09	62.75	28	1745	12852	34942306
Incorrect dose administered	75.28	62.75	38	1735	40477	34914681
SARS-CoV-2 test positive	72.86	62.75	22	1751	5911	34949247
Neutrophil count increased	70.29	62.75	28	1745	17118	34938040
Off label use	68.46	62.75	94	1679	419430	34535728
Disease progression	66.58	62.75	50	1723	108027	34847131
Lymphocyte count decreased	66.03	62.75	29	1744	22593	34932565

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	1313.88	18.59	571	42964	39725	79661128
Diarrhoea	1022.78	18.59	1759	41776	878730	78822123
Ejection fraction decreased	730.44	18.59	363	43172	34214	79666639
Neuropathy peripheral	551.66	18.59	520	43015	140785	79560068
Metastases to central nervous system	430.92	18.59	200	43335	16175	79684678
Polyneuropathy	393.26	18.59	213	43322	23938	79676915
Disease progression	364.31	18.59	475	43060	183887	79516966
Mucosal inflammation	309.67	18.59	286	43249	75294	79625559
Febrile neutropenia	261.37	18.59	459	43076	230540	79470313
Neutropenia	243.24	18.59	505	43030	287205	79413648
Cardiotoxicity	219.06	18.59	115	43420	12124	79688729
Drug ineffective	215.65	18.59	166	43369	1080747	78620106
Neutropenic sepsis	176.40	18.59	134	43401	26930	79673923
Peripheral sensory neuropathy	168.87	18.59	99	43436	12934	79687919
Vascular device infection	165.47	18.59	90	43445	10186	79690667
Palmar-plantar erythrodysaesthesia syndrome	158.63	18.59	137	43398	32997	79667856
Chills	157.72	18.59	300	43235	159934	79540919
Metastases to bone	157.11	18.59	120	43415	24307	79676546
Alopecia	140.86	18.59	357	43178	230998	79469855
Left ventricular dysfunction	137.63	18.59	101	43434	19260	79681593
Metastases to lung	131.94	18.59	96	43439	18067	79682786
Drug interaction	119.43	18.59	39	43496	415144	79285709
Off label use	119.35	18.59	874	42661	906341	78794512
Fall	117.31	18.59	60	43475	487569	79213284
Hypokalaemia	116.97	18.59	249	43286	143791	79557062
Epistaxis	116.16	18.59	214	43321	111301	79589552
Metastases to liver	113.64	18.59	106	43429	28208	79672645
Lymphoedema	112.13	18.59	75	43460	12338	79688515
Interstitial lung disease	110.95	18.59	211	43324	112389	79588464
Nail dystrophy	110.74	18.59	35	43500	978	79699875
Nausea	106.96	18.59	888	42647	956308	78744545
Stomatitis	105.93	18.59	242	43293	146515	79554338
Product dose omission issue	104.71	18.59	8	43527	247529	79453324
Fatigue	101.96	18.59	859	42676	928868	78771985
Cardiac dysfunction	98.09	18.59	47	43488	4077	79696776
Erysipelas	96.67	18.59	65	43470	10785	79690068
Nail toxicity	96.14	18.59	25	43510	338	79700515
Bone pain	90.77	18.59	131	43404	55611	79645242
Toxicity to various agents	88.47	18.59	61	43474	421479	79279374
Dysgeusia	88.22	18.59	131	43404	57046	79643807
Drug hypersensitivity	87.83	18.59	27	43508	298889	79401964
Joint swelling	86.76	18.59	25	43510	288621	79412232
Vomiting	86.43	18.59	640	42895	665188	79035665
Pneumonitis	86.21	18.59	134	43401	60726	79640127
Cellulitis	84.46	18.59	185	43350	108875	79591978
Anaemia	84.36	18.59	471	43064	444544	79256309
Lacrimation increased	84.19	18.59	81	43454	22396	79678457
Arthropathy	83.37	18.59	3	43532	177108	79523745
Device related infection	81.36	18.59	97	43438	34197	79666656
Confusional state	81.19	18.59	36	43499	317961	79382892
Mastitis	81.02	18.59	34	43501	2157	79698696
Condition aggravated	80.61	18.59	93	43442	501031	79199822
Skin toxicity	79.37	18.59	52	43483	8262	79692591
Onycholysis	79.29	18.59	33	43502	2050	79698803
Cardiomyopathy	77.69	18.59	87	43448	28687	79672166
Drug abuse	75.74	18.59	3	43532	162688	79538165
Breast cancer recurrent	74.08	18.59	35	43500	2942	79697911
Nail discolouration	73.48	18.59	35	43500	2996	79697857
Metastasis	73.02	18.59	46	43489	6834	79694019
Delusion of grandeur	72.99	18.59	28	43507	1404	79699449
Decreased appetite	72.70	18.59	374	43161	342044	79358809
Breast pain	72.40	18.59	49	43486	8216	79692637
Neoplasm progression	72.09	18.59	113	43422	51569	79649284
Nail disorder	71.35	18.59	56	43479	11796	79689057
Breast cancer metastatic	70.63	18.59	49	43486	8553	79692300
Therapeutic product effect decreased	70.12	18.59	5	43530	163858	79536995
Abdominal discomfort	69.52	18.59	25	43510	250702	79450151
Drug intolerance	68.83	18.59	29	43506	264090	79436763
Mastectomy	67.70	18.59	25	43510	1127	79699726
Metastases to lymph nodes	66.67	18.59	51	43484	10346	79690507
Product use in unapproved indication	62.85	18.59	29	43506	250330	79450523
Tonsillar disorder	61.84	18.59	24	43511	1242	79699611
Musculoskeletal stiffness	60.85	18.59	11	43524	174997	79525856
Meibomian gland dysfunction	57.47	18.59	15	43520	206	79700647
Constipation	57.17	18.59	305	43230	282745	79418108
Recall phenomenon	57.12	18.59	22	43513	1115	79699738
Pleural effusion	56.34	18.59	191	43344	145071	79555782
Bradycardia	55.59	18.59	5	43530	135552	79565301
Inappropriate schedule of product administration	54.60	18.59	5	43530	133623	79567230
Neutrophil count decreased	52.96	18.59	141	43394	93818	79607035
Radiation skin injury	52.18	18.59	22	43513	1412	79699441
Madarosis	52.05	18.59	27	43508	2775	79698078
Paronychia	51.61	18.59	39	43496	7769	79693084
Hyperfibrinogenaemia	51.42	18.59	12	43523	100	79700753
Metastases to skin	51.27	18.59	23	43512	1716	79699137
Dermatitis acneiform	51.25	18.59	43	43492	9950	79690903
Hepatic enzyme increased	50.96	18.59	18	43517	182592	79518261
Hyperpyrexia	50.71	18.59	35	43500	6057	79694796
Hyperkalaemia	50.39	18.59	3	43532	114395	79586458
Cystitis noninfective	50.24	18.59	21	43514	1319	79699534
Somnolence	49.52	18.59	35	43500	238946	79461907
Excessive eye blinking	48.57	18.59	22	43513	1679	79699174
Cardiac failure	48.54	18.59	190	43345	154652	79546201
Sinusitis	48.51	18.59	23	43512	195478	79505375
Pseudocirrhosis	48.39	18.59	17	43518	663	79700190
Therapy partial responder	47.64	18.59	53	43482	17344	79683509
Myocardial infarction	46.71	18.59	21	43514	184108	79516745
Pain	46.51	18.59	212	43323	703590	78997263
Onychalgia	46.33	18.59	18	43517	934	79699919
Onychoclasis	46.32	18.59	32	43503	5546	79695307
Mobility decreased	46.29	18.59	6	43529	122169	79578684
Hot flush	45.80	18.59	96	43439	54781	79646072
Aortitis	44.64	18.59	20	43515	1487	79699366
Urinary tract infection	44.45	18.59	279	43256	274233	79426620
Dyspepsia	43.98	18.59	145	43390	108542	79592311
Chest discomfort	43.76	18.59	170	43365	137874	79562979
Gait disturbance	43.50	18.59	30	43505	207476	79493377
Systemic lupus erythematosus	43.46	18.59	7	43528	121142	79579711
Metastases to meninges	43.11	18.59	26	43509	3575	79697278
Arthritis	42.67	18.59	6	43529	114874	79585979
HER2 positive breast cancer	42.50	18.59	13	43522	325	79700528
Tumour pain	42.26	18.59	22	43513	2277	79698576
Gastrointestinal haemorrhage	42.18	18.59	14	43521	147705	79553148
Rhinalgia	41.66	18.59	22	43513	2345	79698508
Dry skin	41.35	18.59	105	43430	67890	79632963
Depressed level of consciousness	41.19	18.59	3	43532	96649	79604204
Metastases to spine	41.16	18.59	27	43508	4297	79696556
Alopecia areata	40.80	18.59	20	43515	1823	79699030
Folate deficiency	39.55	18.59	24	43511	3336	79697517
Cardio-respiratory arrest	39.53	18.59	6	43529	108504	79592349
Carbohydrate antigen 15-3 increased	39.30	18.59	17	43518	1162	79699691
Hypertransaminasaemia	39.15	18.59	40	43495	11884	79688969
Platelet count decreased	38.75	18.59	209	43326	194455	79506398
Nail infection	38.58	18.59	21	43514	2378	79698475
Lymphocyte count abnormal	38.41	18.59	18	43517	1485	79699368
Exposure during pregnancy	38.23	18.59	5	43530	101127	79599726
Dehydration	38.17	18.59	249	43286	247938	79452915
Lower respiratory tract infection	37.64	18.59	155	43380	129065	79571788
Nasal discomfort	37.60	18.59	28	43507	5455	79695398
Feeling abnormal	37.58	18.59	20	43515	159179	79541674
Vessel puncture site bruise	37.20	18.59	13	43522	499	79700354
Biliary sepsis	37.16	18.59	18	43517	1599	79699254
Nasal disorder	37.02	18.59	24	43511	3745	79697108
Treatment failure	36.60	18.59	24	43511	170462	79530391
Leukopenia	36.53	18.59	143	43392	116370	79584483
Blood magnesium decreased	36.38	18.59	45	43490	16467	79684386
Infusion related reaction	36.01	18.59	232	43303	230005	79470848
Red cell distribution width increased	35.96	18.59	43	43492	15199	79685654
Hair texture abnormal	35.94	18.59	23	43512	3511	79697342
Discomfort	35.70	18.59	12	43523	125605	79575248
Hyperchlorhydria	35.68	18.59	19	43516	2060	79698793
Pyrexia	35.40	18.59	543	42992	678166	79022687
Enterocolitis infectious	35.08	18.59	21	43514	2848	79698005
Delirium	35.02	18.59	3	43532	84624	79616229
Injection site pain	34.21	18.59	14	43521	129824	79571029
Osteonecrosis of jaw	34.20	18.59	74	43461	43152	79657701
Vascular fragility	34.12	18.59	9	43526	129	79700724
Osteoarthritis	33.78	18.59	4	43531	87305	79613548
Pericarditis	33.24	18.59	8	43527	104228	79596625
Hallucination	32.99	18.59	4	43531	85741	79615112
Lymphocyte count decreased	32.99	18.59	77	43458	47212	79653641
Colitis	32.56	18.59	101	43434	73206	79627647
Vulvovaginal candidiasis	32.31	18.59	19	43516	2495	79698358
Hair colour changes	32.17	18.59	23	43512	4209	79696644
White blood cell count abnormal	32.13	18.59	26	43509	5719	79695134
Neurotoxicity	32.07	18.59	61	43474	32457	79668396
Back pain	31.97	18.59	279	43256	303901	79396952
Odynophagia	31.86	18.59	35	43500	11292	79689561
Gastrointestinal toxicity	31.84	18.59	30	43505	8079	79692774
Hepatic lesion	31.73	18.59	28	43507	6931	79693922
Blood creatine increased	31.55	18.59	32	43503	9423	79691430
Paraesthesia	30.91	18.59	183	43352	176140	79524713
Nasal congestion	30.91	18.59	3	43532	76549	79624304
Post-traumatic pain	30.81	18.59	11	43524	450	79700403
Suicidal ideation	30.80	18.59	3	43532	76337	79624516
Pneumonitis chemical	30.55	18.59	11	43524	461	79700392
Onychomadesis	29.91	18.59	24	43511	5218	79695635
Dyspnoea	29.67	18.59	643	42892	856382	78844471
Axillary pain	29.63	18.59	17	43518	2132	79698721
Myalgia	29.60	18.59	188	43347	185453	79515400
Granulocyte count decreased	29.56	18.59	16	43519	1792	79699061
Acute interstitial pneumonitis	29.27	18.59	14	43521	1209	79699644
Rhabdomyolysis	29.05	18.59	10	43525	103121	79597732
Injury	28.89	18.59	4	43531	77492	79623361
Hospitalisation	28.58	18.59	8	43527	94228	79606625
Weight increased	28.28	18.59	69	43466	277317	79423536
Osteitis condensans	28.18	18.59	6	43529	31	79700822
Cerebrovascular accident	28.09	18.59	26	43509	155266	79545587
Renal impairment	27.86	18.59	27	43508	157756	79543097
Asthma	27.69	18.59	20	43515	135075	79565778
Affective disorder	27.48	18.59	28	43507	8291	79692562
Breast disorder	27.46	18.59	16	43519	2065	79698788
Breast inflammation	27.43	18.59	8	43527	169	79700684
Impaired healing	27.42	18.59	7	43528	87648	79613205
Catheter site bruise	27.14	18.59	10	43525	448	79700405
Vaginal prolapse	27.05	18.59	9	43526	297	79700556
Product use issue	26.63	18.59	46	43489	209776	79491077
Osteosclerosis	26.61	18.59	20	43515	3951	79696902
Hypothalamo-pituitary disorder	26.56	18.59	13	43522	1181	79699672
Cardiac arrest	26.47	18.59	33	43502	172063	79528790
Pituitary tumour	26.28	18.59	13	43522	1209	79699644
Gastritis	26.00	18.59	71	43464	47922	79652931
Agitation	25.87	18.59	11	43524	99704	79601149
Palmar erythema	25.77	18.59	15	43520	1932	79698921
Bone marrow infiltration	25.67	18.59	11	43524	735	79700118
Central nervous system lesion	25.62	18.59	34	43501	13334	79687519
Pulmonary hypoplasia	25.40	18.59	6	43529	53	79700800
Keratitis	25.11	18.59	20	43515	4302	79696551
Hand dermatitis	25.02	18.59	9	43526	376	79700477
Rectal haemorrhage	25.01	18.59	95	43440	76205	79624648
Blood glucose increased	24.92	18.59	16	43519	114959	79585894
Coma	24.71	18.59	12	43523	100637	79600216
Tongue coated	24.70	18.59	13	43522	1376	79699477
Metastases to bone marrow	24.64	18.59	11	43524	811	79700042
Depression	24.47	18.59	51	43484	216739	79484114
Metastatic neoplasm	24.43	18.59	21	43514	5021	79695832
Rhinorrhoea	24.35	18.59	94	43441	75980	79624873
Flushing	24.23	18.59	104	43431	88164	79612689
Neutrophil count increased	24.03	18.59	51	43484	29345	79671508
Disorientation	23.98	18.59	3	43532	62773	79638080
Tidal volume decreased	23.97	18.59	6	43529	69	79700784
Electrocardiogram QT prolonged	23.40	18.59	10	43525	90376	79610477
Duodenal ulcer perforation	23.35	18.59	4	43531	66207	79634646
Overflow diarrhoea	23.27	18.59	7	43528	165	79700688
Nail bed bleeding	23.22	18.59	10	43525	676	79700177
Haemorrhoids	23.19	18.59	50	43485	29078	79671775
Mean platelet volume decreased	23.15	18.59	16	43519	2774	79698079
Therapeutic product effect incomplete	23.02	18.59	26	43509	141619	79559234
Systolic dysfunction	22.99	18.59	18	43517	3777	79697076
Skin infection	22.85	18.59	38	43497	18207	79682646
Adverse event	22.70	18.59	3	43532	60211	79640642
Cough	22.45	18.59	302	43233	366487	79334366
Urticaria	22.25	18.59	42	43493	185159	79515694
Dental fistula	22.19	18.59	9	43526	523	79700330
Intracranial pressure increased	22.18	18.59	25	43510	8297	79692556
Swelling	22.00	18.59	54	43481	216657	79484196
Mucosal dryness	21.82	18.59	17	43518	3542	79697311
Hypoaesthesia	21.76	18.59	170	43365	179182	79521671
Perforation	21.60	18.59	12	43523	1414	79699439
Catheter site pain	21.26	18.59	20	43515	5376	79695477
Malignant neoplasm progression	21.22	18.59	137	43398	135853	79565000
Urinary tract disorder	21.07	18.59	17	43518	3725	79697128
Dandy-Walker syndrome	20.79	18.59	5	43530	48	79700805
Stress cardiomyopathy	20.79	18.59	28	43507	11138	79689715
Nail bed tenderness	20.76	18.59	8	43527	406	79700447
Orthostatic hypotension	20.70	18.59	3	43532	56161	79644692
Naevus haemorrhage	20.65	18.59	6	43529	125	79700728
Spinal pain	20.55	18.59	33	43502	15359	79685494
Wheezing	20.55	18.59	20	43515	116644	79584209
Paralysis recurrent laryngeal nerve	20.38	18.59	6	43529	131	79700722
Breast neoplasm	20.29	18.59	10	43525	922	79699931
Influenza like illness	20.07	18.59	85	43450	71622	79629231
Anxiety	20.07	18.59	69	43466	248443	79452410
Gingival swelling	19.94	18.59	18	43517	4591	79696262
Secondary cerebellar degeneration	19.93	18.59	5	43530	58	79700795
Hypoglycaemia	19.59	18.59	16	43519	101578	79599275
Cognitive disorder	19.31	18.59	7	43528	69919	79630934
Nephrolithiasis	19.29	18.59	3	43532	53288	79647565
Plasma cell myeloma	19.27	18.59	3	43532	53256	79647597
Tumour marker increased	19.10	18.59	17	43518	4255	79696598
Blood cholesterol increased	19.05	18.59	11	43524	83709	79617144
Inflammation	19.05	18.59	14	43521	93739	79607114
Coronary artery disease	19.05	18.59	6	43529	65468	79635385
Vulvovaginal dryness	19.04	18.59	13	43522	2211	79698642
Recurrent cancer	19.02	18.59	14	43521	2679	79698174
Respiratory tract infection	18.83	18.59	64	43471	48625	79652228
Urogenital prolapse	18.74	18.59	4	43531	21	79700832
Corneal disorder	18.69	18.59	13	43522	2278	79698575
Overdose	18.62	18.59	46	43489	184160	79516693

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FD02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
ATC	L01XY02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Combinations of antineoplastic agents
FDA MoA	N0000020008	HER2/Neu/cerbB2 Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
FDA EPC	N0000175661	HER2/neu Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
HER2-positive rectal cancer	indication	363351006	DOID:1993
HER2-positive colon cancer	indication	363406005	DOID:219
HER2-positive carcinoma of breast	indication	427685000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	ANTIBODY BINDING				UNKNOWN	DRUG LABEL

External reference:

ID	Source
D05446	KEGG_DRUG
4031566	VUID
N0000185031	NUI
4031566	VANDF
CHEMBL2007641	ChEMBL_ID
C485206	MESH_SUPPLEMENTAL_RECORD_UI
5046	IUPHAR_LIGAND_ID
DB06366	DRUGBANK_ID
1298944	RXNORM
190566	MMSL
28589	MMSL
d07874	MMSL
014427	NDDF
704226002	SNOMEDCT_US
704227006	SNOMEDCT_US
C1328025	UMLSCUI
8380	INN_ID
K16AIQ8CTM	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PERJETA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-145	INJECTION, SOLUTION, CONCENTRATE	30 mg	INTRAVENOUS	BLA	31 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-245	INJECTION, SOLUTION	1200 mg	SUBCUTANEOUS	BLA	30 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-245	INJECTION, SOLUTION	1200 mg	SUBCUTANEOUS	BLA	30 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-260	INJECTION, SOLUTION	600 mg	SUBCUTANEOUS	BLA	30 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-260	INJECTION, SOLUTION	600 mg	SUBCUTANEOUS	BLA	30 sections